Wire · opportunities
FDA is considering a competency-based approach to evaluating generative AI-enabled ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 August 2026 · Fusion42 review
The FDA is considering a shift to a competency-based framework for evaluating generative AI-enabled medical devices, focusing on ongoing performance assessments rather than single-point safety and efficacy reviews.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure, and 14 sources have reported it between 18 Aug 2026 and 15 Sep 2026.
◆ ◆ The Wire takeaway
You need to prepare for a regulatory environment where AI medical devices face continuous compliance checks instead of one-off clearances. This opens opportunities for faster innovation cycles but demands robust ongoing performance tracking.
◆ Coverage
14 sources · first reported 18 Aug 2026 · latest 15 Sep 2026
◆ Related on Wire
◆ Topics